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Bioactive Follicle-Stimulating 
Hormone 
Inese Z. Beitins and Vasantha Padmanabhan 
Specific and sensitive in vitro bioassays suitable for measurement of 
follicle-stimulating hormone (FSH) in small quantities of serum and 
urine have recently been validated. Comparisons of bioassay (B-FSH) 
potencies with immunoassay (I-FSH) estimates and chromatofocusing 
patterns have facilitated new discoveries regarding the regulation of 
FSH biosynthesis, storage, secretion, serum concentrations and target 
cell responsiveness, plasma clearance, and the significance of excreted 
forms. A review of recent studies reveals that luteinizing hormone and 
FSH, as well as B-FSH and I-FSH, appear to be differentially regulated 
by GnRH, GnRH agonists and antagonists, sex steroids and gonadal 
peptides in both sexes, with significant differences between the sexes. 
The results support the overall hypotheses that the quality as well as the 
quantity of FSH are significant contributors to target cell signal 
transduction and that distinct FSH isoforms with different functional 
capabilities influence the expression of acute (ovulation) and chronic 
reproductive events. (Trends Endocrlnol Metab 1991; 2: 145-15 1) 
Research during the last two decades has 
firmly established that follicle-stimulat- 
ing hormone (FSH), like other glycopro- 
teins, is not a unique protein, but rather 
a family of heterogeneous isoforms of 
varying immunologic and bioactive po- 
tencies. Such mixes of isoforms are 
found within the pituitary, resulting 
from differential promoter action, alter- 
native splicing, induction of point muta- 
tions during biosynthesis, or posttransla- 
tional changes, including carbohydrate 
incorporation prior to or during granule 
formation within the gonadotrope. Upon 
secretion, these molecular variations de- 
termine tertiary structure and metabolic 
clearance. Molecules lacking sialic acid 
residues (relatively less acidic) have 
shorter half-lives within the circulation, 
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yet bind avidly to the target tissue recep- 
tors, whereas those with full carbohy- 
drate complements, including sialic acid, 
circulate longer, but bind less well in 
vitro. Therefore, it is the proportion of 
the various isofotms that reach the 
target cell receptors that influences not 
only receptor binding, but also signal 
transduction, in a variety of measurable 
biologic end points. 
A biologic potency can be defined as 
the equivalent response obtained by the 
testing material to a known dose of a 
purified reference preparation upon a 
measurable biologic response within an 
organism, organ, or cellular system in 
vitro. Various postreceptor-binding end 
points have been used for FSH assays. In 
in vivo bioassays, hypophysectomized 
mice or immature rats were treated with 
pituitary or urinary extracts, which had 
been extensively purified chemically and 
concentrated (serum could not be used). 
Each assay required a large number of 
animals, whose overall health and 
weight could be detrimentally affected 
by remaining toxins or foreign proteins 
within the test materials, thus leading to 
poor reproducibility of results. Though 
the assays incorporated metabolic clear- 
ance, they were relatively insensitive 
compared with immunoassays. With im- 
munoassay development, standards and 
antibodies were preferentially selected 
that would provide the desired sensitiv- 
ity and exhibit parallel responses to the 
test materials. It became evident early, 
however, that comparisons of in vivo 
bioassay responses of extracted rat pitui- 
tary FSH to immunoassay potencies did 
not provide consistent bioactive to im- 
munoreactive (B-I) ratios. Furthermore, 
steroid treatment of castrated rats al- 
tered the B-I ratio of FSH as well as its 
clearance (Bogdanove et al. 1973). These 
studies led to the hypothesis that both 
G&I-I stimulation and steroid modula- 
tion altered not only the quantity but 
also the quality of the hormone (Chappel 
et al. 1983). 
These initial observations were ex- 
tended to other animal species, such as 
the hamster (Chappel et al. 1983). A 
series of experiments studying FSH 
isofoxm distribution patterns following 
chromatofocusing and measuring hormo- 
nal potencies by means of receptor bind- 
ing, in vitro bioassay and immunoassay 
methods confirmed that GnRH stimula- 
tion and sex steroid modulation, as in 
the estrous cycle or throughout puberty, 
induced shifts within the FSH isoform 
distribution patterns. Shifts from the 
acidic to relatively more basic isoforms 
also resulted from neuraminidase treat- 
ment, confirming the importance of the 
presence of sialic acid upon the p1 of the 
FSH molecule. 
Though sensitive and precise in vitro 
bioassays utilizing rat interstitial cell 
testosterone production (RICT) had been 
validated and widely used for measure- 
ments of dynamic changes in the B-I 
ratios of luteinizing hormone (LH) in a 
variety of physiologic and pathophysiol- 
ogic conditions (Dufau and Veldhuis 1987) 
the development of similar in vitro bioas- 
says suitable for measurement of FSH in 
unextracted serum lagged behind. In rat 
granulosa cells, aromatase could be relia- 
bly induced by FSH standards, yet the 
addition of serum to the in vitro system 
depressed the biologic response and led 
to nonparallelism. This problem was 
overcome by treating serum with 12% 
polyethylene glycol (PEG) (Jia and Hsueh 
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1985). We, on the other hand, optimized 
the conditions of the rat Sertoli cell 
aromatase induction assay first described 
by Van Damme et al. (1979). By improv- 
ing the sensitivity severalfold, we are now 
able to reliably determine FSH in unex- 
tracted serum (Padmanabhan et al. 1987) 
and urine. 
Building upon the experience with 
bioassayed (B)-LH and its comparisons 
with immunologic potencies, which ad- 
dressed sex differences, regulation of 
secretion by GnRH and modulation by 
sex steroids, plasma clearance, and re- 
sponses to GnRH agonists and antago- 
nists, we now describe similar experi- 
ences with the newly validated in vitro 
FSH bioassays. Because these in vitro 
bioassays, unlike the immunoassays, have 
only limited species specificity, they can 
be utilized in animal models either to 
confirm regulatory mechanisms impos- 
sible to study in the human or chart new 
territory in reproductive endocrinology 
in a variety of species where FSH meas- 
urements were previously not possible. 
Within our own work, we have tested 
the overall hypothesis, which was first 
proposed by Chappel et al. (1983), that 
FSH isoforms have different physiologic 
functions, with the sialylated (longer 
half-lived, but less reactive in the in vitro 
assay) playing an important role in 
organ growth and the maintenance of 
reproductive function, whereas the rela- 
tively more basic (less sialylated, short 
half-lived) play an important role in 
dynamic events such as ovulation. 
?? Comparison of Bioassays of FSH 
and B-FSH Serum Concentrations 
in Physiologic States 
The major differences between the gran- 
ulosa aromatase induction assay (GABA) 
and Sertoli cell aromatase assay, which 
have been recently reviewed (Wang 1988; 
Hsueh et al. 1989), are (a) the selection of 
target tissues from rats of different sexes 
and reproductive ages; (b) pretreatment 
of serum, but not urine, with PEG in the 
GABA, but not Sertoli cell assay: (c) the 
choice of standards with LER 907, IRP 
78/549, Pergonal, and NIH-hFSH-3 used 
by various investigators for GABA, but 
the pituitary standards (NM-hFSH-2 and 
NM-hFSH-3) for the Sertoli cell assay; 
and (d) the expression of B-FSH poten- 
cies as ID/L as related to the in vivo FSH 
biopotency of the World Health Organi- 
zation Reference Preparation for the 
GABA and micrograms per liter of puri- 
fied standard for the Sertoli cell assay. 
Without actual comparisons of B-FSH 
potencies of the same preparations in 
both assay systems, it is not valid to 
convert the values obtained in one to 
those obtained with a different standard 
in the other. Similar discrepancies in the 
selection of antibodies, standards, and 
assay conditions exist within the respec- 
tive FSH immunoassays. Therefore, 
though the results from various studies 
cannot be compared quantitatively, 
trends in circulating and excreted levels 
of B-FSH can be established and com- 
pared. Likewise, variations in the FSH 
B-I ratio within each assay system can 
reflect variable FSH isoform distribu- 
tion, which can be confirmed by chro- 
matofocusing. Physiologic validation of 
both assays (GABA and Sertoli cell) was 
accomplished by measurement of B- 
FSH in single serum samples obtained 
nist therapy as well as orchidectomy 
have also been reported. Young men 
have circulating B-FSH concentrations 
of 7.7 + 2.0 ID/I_ (mean&SE), with a 
mean B-I ratio of 2.7 + 0.3 (Tenover et 
al. 1987). Elderly men and those with 
idiopathic azoospermia have identical 
mean serum B-FSH concentrations, but, 
owing to increased serum I-FSH levels, 
lower mean serum FSH B-I ratios 
(1.4 i: 0.2 and I.5 + 0.5, respectively) 
(Tenover et al. 1987; Wang et al. 1987). 
Men with severe oligospermia, on the 
other hand, had elevated serum B- and 
I-FSH concentrations, with a B-I ratio of 
1.7 f 0.3. Elderly men with prostatic 
carcinoma had mean serum B-FSH con- 
centrations of 19.7 * 4.1 ID/L, with a 
B-I ratio of 1.7 k 0.2 (Huhtaniemi et al. 
1988). Treatment with a GnRH analogue 
decreased serum I-FSH concentrations 
to a greater extent than serum B-FSH 
concentrations, with a resulting B-I ratio 
of 6.7 f 0.8 in 2-3 weeks of treatment 
from cross-sectional studies in men and 
women. B-FSH was not detected in the 
sera from hypophysectomized patients 
or women treated with oral contracep- 
tives. With both assays, serum B-FSH 
values were lowest in men, followed by 
women during the luteal and follicular 
phases of their menstrual cycles. Sera 
from postmenopausal women and women 
with premature ovarian failure contained 
the highest B-FSH concentrations, which 
exceeded values observed during the 
midcycle of menstruating women. 
?? Serum B-FSH Levels and FSH B-I 
Ratios in Men 
With the GAB assay, cross-sectional stud- 
ies have been performed comparing 
serum B-FSH concentrations and B-I 
ratios in normal young men, elderly 
men, and men with idiopathic azoosper- 
mia, oligospermia, and prostatic cancer. 
The effects of GnRH agonist and antago- 
and a gradual decline to pretreatment 
B-I ratio levels by 6 months. Orchidec- 
tomy at this point caused an initial 
increase in 2 weeks to a mean serum 
FSH B-I ratio of 6.6-6.8, with a decline 
toward pretreatment ratios during the 
next 3 months. In normal men treated 
with GnRH agonists, with or without 
testosterone enanthate, the serum FSH 
B-I ratios remained unchanged (Pavlou 
et al. 1988). Five men treated with a 
potent GnRH antagonist clearly demon- 
strated that serum B-FSH levels were 
suppressed to a greater extent than were 
serum I-FSH levels (Dahl et al. 1986). 
These effects led to a dramatic lowering 
of the serum FSH B-I ratio. Several 
conclusions could be reached: (a) serum 
B and I-FSH concentrations did not 
increase or decrease in parallel in vari- 
ous pathophysiologic conditions; (b) in 
older men, or those with inadequate 
spermatogenesis, the serum FSH El-1 
ratio was significantly lower than in 
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younger men or following orchidectomy; 
(c) treatment with GnRH agonists failed 
to decrease serum B-FSH concentrations 
to the same degree as serum I-FSH or 
I-LH concentrations; and (d) treatment 
with GnRH antagonists preferentially 
depressed serum B-FSH over I-FSH. It 
therefore appeared that serum B-FSH 
synthesis and secretion were differen- 
tially regulated from that of LH and that 
testicular factors depressed B-FSH se- 
cretion. These inhibitory effects were 
removed upon orchidectomy. 
?? Serum B-FSH Concentrations 
and FSH B-I Ratios in Women 
In postmenopausal women and women 
with premature ovarian failure, both B- 
and I-FSH concentrations were elevated, 
with the resulting serum FSH B-I ratios 
not significantly different from those of 
cycling women in the follicular phase or 
young men (Wang 1988). Treatment 
with varying doses of a potent GnRH 
antagonist resulted in a 51%-63% de- 
crease in serum I-LH and a 14%33% 
decrease in I-FSH. B-LH and B-FSH 
were suppressed to a greater extent than 
the corresponding immunoreactive go- 
nadotropins (Mortola et al. 1989). This 
resulted in a 27% decline in the B-I ratio 
for FSH. 
Serum B-FSH concentrations have 
been determined in daily blood samples 
obtained throughout the menstrual cycle 
by utilizing the GABA (Jia et al. 1986; 
Fauser et al. 1989) and the Sertoli cell 
assay (Padmanabhan et al. 1988b; Be- 
itins et al. 1990). With the GABA, the 
serum B-FSH concentrations paralleled 
those of serum I-FSH, with no change in 
the FSH B-I ratio throughout all phases 
of the menstrual cycle. The FSH B-I 
ratio ranged from 1.4 to 3.4, with a mean 
of 2.5. Urinary B-FSH levels, obtained in 
daily first morning void samples, how- 
ever, exhibited marked elevations in 
urinary B-FSH concentrations, which 
coincided with the LH peak (Dahl et al. 
1987). There was a highly significant 
correlation between serum and urinary 
B-FSH. Infusion of an antagonist of 
GnRH at 30 ng/kg h in women during 
the midfollicular phase suppressed B- 
FSH levels by 64%, but I-FSH only by 
29%. When the GnRH antagonist was 
given subcutaneously at a higher dose of 
80 ug/kg twice daily for 3 days during the 
midfollicular phase, the B-FSH response 
was biphasic, with a maximal decrease until term, but 6 weeks postpartum 
on the second day, returning to basal B-FSH levels were low and did not 
levels by the third (Kessel et al. 1988). increase with GnRH stimulation. 
Having used the Sertoli cell assay, 
Padmanabhan et al. (1988b) reported 
that women during the menstrual cycle 
had significantly higher B-FSH con- 
centrations during the midcycle than the 
follicular phase. The serum FSH B-I 
ratio was the highest during this phase of 
the menstrual cycle and the lowest dur- 
ing the luteal phase. These changes in 
serum B-FSH reflected shifts in the 
distribution of FSH isoforms from the 
acidic to a relatively basic p1 (with 
higher B-I ratios) upon chromatofo- 
cusing. These results were compatible 
with the hypothesis that less sialylated, 
shorter-lived FSH isoforms circulated 
during the midcycle period and may 
participate in dynamic functions such as 
ovulation. The relative shift of the FSH 
isoform biosynthesis and secretion could 
be due to either increased GnRH pulse 
frequency or the rising sex steroid val- 
ues. These potent FSH isoforms could 
participate in the induction of plasmino- 
gen activator, activating plasmin, finally 
leading to the breakdown of collagen 
fibers present in the tissues of the ovulat- 
ing follicles (Hsueh et al. 1989). 
?? Serum B-FSH Concentrations 
During Development and Puberty 
In human fetuses, who have had chor- 
docentesis for medical indications but 
were found to be normal, serum B-FSH 
concentrations were higher in girls than 
boys at 20-25 weeks of gestation, but 
declined and were no longer signifi- 
cantly different between the sexes at 35 
and 40 weeks of gestation (unpublished 
data). In samples drawn simultaneously 
from the mother and by chordocentesis, 
the maternal B-FSH levels were - 3 
times higher than in the fetus. The 
B-FSH serum concentrations during fetal 
life near term were -10 times higher 
than those during pubertal development 
in boys and girls. 
During the menstrual cycle studies, 
several women had become pregnant. 
Serum B-FSH levels, in contrast to I- 
FSH levels, increased significantly from 
postovulation day 7 to the end of the 
menstrual cycle study period. The serum 
FSH B-I ratio increased from 2.5 on the 
LH peak day to 70 by day 15 after the LH 
peak day. In another study, blood sam- 
ples had been obtained every 10 min for 
10 h on days 10,20, and 27 after the LH 
peak in a pregnant woman. The serum 
B-FSH concentrations appeared pulsa- 
tile and the FSH B-I ratio was likewise 
elevated. This FSH-like bioactive mate- 
rial was not due to cross reaction with 
hCG, j3 subunit, a-hCG, a-fetoprotein, or 
human placental lactogen. Removal of 
steroids by charcoal extraction did not 
alter the final results. FSH-like activity 
was present in the media from placental 
incubates, with an FSH B-I ratio of 47.1 
(Padmanabhan et al. 1989a). FSH-like 
bioactive material was also secreted by 
choriocarcinoma cells in culture. The 
increase of B-FSH in pregnancy serum 
was confirmed by FSH isoform distribu- 
tion patterns. There was a progressive 
increase in serum B-FSH-like activity 
From cross-sectional as well as longi- 
tudinal studies of bioactive gonadotropin 
concentrations throughout puberty, 
though B-LH levels rose progressively 
through each stage of puberty, B-FSH 
serum concentrations did not change 
significantly (Reiter 1982; Beitins et al. 
1990). The serum B-FSH concentrations 
were as high during the prepubertal 
period as during later stages of puberty 
when both boys and girls had matured 
and sex steroid concentrations were sig- 
nificantly increased. Serum I-FSH con- 
centrations were significantly higher dur- 
ing puberty in girls than boys, with the 
resulting serum FSH B-I ratio signifi- 
cantly lower in girls than boys. Serum 
B-FSH levels during puberty were not 
significantly different from those of men 
and women during the follicular phase 
of the menstrual cycle, but were lower 
than during the periovulatory period. 
Similar findings have been reported in 
girls with precocious puberty (Wang et 
al. 1990). Basal serum B-FSH levels were 
not significantly different in patients 
with precocious puberty, premature 
thelarche, or prepubertal controls. After 
12 months of GnRH agonist therapy, 
both I-FSH and B-FSH concentrations 
were suppressed in patients with precoc- 
ity. The serum FSH B-I ratio was not 
changed. In 12 volunteers from ages 
5-12 years, however, overnight urinary 
excretion of B-FSH, expressed per mil- 
ligram of creatinine, revealed a gradual 
increase from childhood to pre- and 
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postmenarchalperiod (Fauseret al. 1989). 
The number of subjects per group was 
small (n = 3) and the differences in 
urinary concentrations increased less 
than twofold. 
?? Regulation of B-FSH Secretion 
Role of GnRH 
From the preceding studies, it is appar- 
ent that GnRH and GnRH agonists and 
antagonists influence B- and I-FSH se- 
cretion and potency. This was further 
confirmed by administering small pulses 
of GnRI-I (0.025 ug/kg) intravenously at 
hourly intervals for 3-5 days to boys with 
idiopathic hypogonadotropic hypogona- 
dism (Padmanabhan et al. 1988a). Serum 
B-FSH concentrations increased signifi- 
cantly after 9 1% of the GnRH doses, even 
at times when there were no increases in 
serum I-FSH, I-LH, or sex steroid con- 
centrations. The serum B-FSH responses 
occurred consistently within 20 min 
after the GnRH administration, but the 
B-FSH levels had returned to baseline by 
60 min, indicating rapid clearance of the 
newly secreted B-FSH. 
In midpubertal boys who had blood 
withdrawn every 10 min from 2000 to 
0800 h, B-FSH was secreted in clearly 
discernible pulses before, during, and 
after the onset of sleep (Hassing et al. 
1990). In association with the increased 
frequency and amplitude of I-LH pulses, 
there was a minimal, but significant, 
increase in mean B-FSH levels 0, = 0.046), 
pulse frequency (p = 0.045), but not B- 
FSH pulse amplitude. When testosterone 
was infused at the rate of the adult male 
production rate, the mean serum I-LH 
rise and nocturnal increase in LH pulse 
frequency were abolished without an 
effect on B-FSH pulsatility. 
To dissect the relative contribution of 
GnRH versus steroids further, nutrition- 
ally growth-retarded ovariectomized 
lambs were studied during nutritional 
repletion (Padmanabhan et al. 1989b). 
In this animal model, LH secretory 
pulses were utilized as an index of 
endogenous GnRH secretion. During the 
period of nutritional restriction, I-LH 
and I-FSH levels were low and relatively 
apulsatile in serial blood samples ob- 
tained every I2 min for 4 h. In contrast, 
serum B-FSH showed a pulsatile secre- 
tory pattern that became even more 
apparent with nutritional repletion. In 
contrast to increasing I-LH pulse fre- 
quency, FSH pulse frequency remained 
stable, whereas FSH pulse amplitude 
increased. Serum B-FSH pulse ampli- 
tudes were 57 f 7% greater than I-FSH 
pulses. The asynchronous occurrence of 
FSH pulses in the absence of I-LH pulses 
led us to speculate that FSH may be 
more sensitive to small changes in GnRH 
secretion than I-LH or that a hypotha- 
lamic releasing factor specific for FSH 
may be present. 
Effect of Steroids on B-FSH Secretion 
In addition to the study with the acute 
testosterone infusion in midpubertal boys 
described above, the effects of acute (24 
h) infusions and long-term steady-state 
infusions of dihydrotestosterone (DHT) 
and estradiol (E,) in normal men have 
been performed. Men infused with E, to 
elevate their mean serum E, to twice 
their endogenous E, levels for 24 h did 
not have a significant change in their 
mean serum B-FSH levels. Likewise, 
when DHT or E, was infused for a total 
of 5’12 days and blood withdrawn every 
10 min for the last 28 h, the mean serum 
B-FSH concentrations in pooled samples 
were not significantly different whether 
measured with the Sertoli cell aromatase 
induction or GABA (Urban et al. 1990). 
Therefore, it appeared that neither T, 
DHT, or E, significantly altered mean 
B-FSH serum concentrations in midpu- 
bertal boys and men. 
In women with gonadal dysgenesis 
treated with estrogenic steroids for 21 
days, there was an initial parallel decline 
in the B-and I-FSH levels for about the 
first 14 days with a stable serum FSH B-I 
ratio. During week 3, however, I-FSH 
levels continued to decline while serum 
B-FSH levels remained stable, leading to 
a significant increase in the serum FSH 
B-I ratio (Padmanabhan et al. 1988b). 
This increase in the FSH B-I ratio was 
similar to that obsetved during the periovu- 
latory period of the menstrual cycle, 
when both GnRH pulse frequency and 
amplitude as well as serum E, levels 
were increasing. 
In women with polycystic ovary syn- 
drome (PCOS), endogenous serum an- 
drogens are elevated. Irrespective of 
whether the patients had elevated ba- 
seline and post-GnRH stimulation I-LH 
levels or whether they were relatively 
normal (group II), mean serum B-FSH 
concentrations were higher than serum 
I-FSH concentrations and similar to 
levels found in normal women during 
the follicular phase (unpublished data). 
When E, and progesterone were re- 
placed at luteal concentrations for 20 
days, mean serum I-FSH concentrations 
decreased significantly (2.3 + 0.2 to 
0.6 + 0.1 ug/L), while mean serum B- 
FSH concentrations remained stable 
(3.4 +0.2 vs 3.1 + 0.3 l.rg/L.). The re- 
sulting serum FSH B-I ratio increased 
from 1.6 fO.l to 7.0+ 2.6 07 < 0.01). 
The mean serum B-FSH concentrations 
in the presence of luteal phase levels of 
E, and progesterone were significantly 
higher than during the spontaneous 
luteal phases (1.4 f 0.2 ug/L). These 
results indicated that serum B-FSH lev- 
els in PCOS were slightly higher than in 
normal controls but did not suppress 
with luteal phase E, and P administra- 
tion in a manner similar to serum I-FSH. 
The low serum B-FSH levels during the 
spontaneous luteal phase were probably 
related to secretions from the corpus 
luteum itself. 
?? FSH Isoform Distribution Patterns 
and FSH Clearance in the Human 
FSH isoform distribution patterns are 
difficult to obtain from unaltered human 
tissues and biologic fluids. Pituitaries 
obtained postmortem are subject to 
autolysis and those removed because of 
tumors may not synthesize normal hormo- 
nal isoforms. Plasma concentrations of 
FSH are relatively low. Nevertheless, 
FSH isoform distribution patterns from 
FSH-secreting tumors confirmed an- 
imal studies and revealed that the high- 
est FSH B-I ratios were present in the 
less acidic fractions of the chromatofo- 
cused eluates (Padmanabhan et al. 
1988b). FSH extracted from pituitaries 
was qualitatively different in young 
women from FSH derived from men 
and elderly women (Wide and Hobson 
1983). FSH isoform distribution pat- 
terns from chromatofocused serum re- 
vealed an increase in the relatively less 
acidic FSH isoforms during the periovu- 
latory period as well as following chronic 
estrogenic therapy in women with gona- 
da1 dysgenesis. Therefore, during high 
estrogenic states, circulating FSH 
isoforms are less acidic (less sialic acid) 
and have a shorter circulation time, but 
retain binding to target tissue receptors. 
Conversely, during states of low estro- 
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genie stimulation, such as the follicular 
phase of the menstrual cycle (Pad- 
manabhan et al. 1988b), men, postmen- 
opausal women, and castrated men 
(Wide and Hobson 1983), the charge of 
the FSH is relatively more acidic. Treat- 
ment with neuraminidase eliminated 
the FSH charge differences (Wide 1986). 
GnRH stimulation in patients with 
Turner’s syndrome likewise induced the 
appearance of less negatively charged 
FSH isoforms in electrophoretic mo- 
bility studies (Wide and Albertsson- 
Wiklund 1990). Finally, infusion of a 
GnRH antagonist into hypogonadal 
women increased basic FSH isoforms, 
as determined by chromatofocusing 
(Dahl et al. 1988a). These isoforms 
bound to granulosa cell FSH receptors, 
but were devoid of biologic activity and, 
in fact, inhibited FSH action, 
In addition to the differential binding 
to FSH receptors and induction of bio- 
logic responsiveness, different FSH 
isoforms are cleared from the circulation 
at different rates. FSH extracted from 
pituitaries of young women was cleared 
from the circulation of mice at a faster 
rate than FSH from men or elderly 
women (Wide and Wide 1984). Studies 
combining studies of molecular mobility 
on electrophoresis with metabolic clear- 
ance rate determined that the less nega- 
tively charged FSH isoforms are cleared 
more rapidly (Wide 1986). Therefore, the 
charge (PI or sialic acid content) regu- 
lates the survival of FSH within the 
circulation. 
From the studies utilizing in vitro FSH 
bioassays, the disappearance of newly 
secreted FSH in response to GnRH in 
patients with idiopathic hypogona- 
dotropic hypogonadism is -60 min (Pad- 
manabhan et al. 1988a). This is in 
contrast to the determinations based on 
I-FSH measurements after hypophysec- 
tomy or bolus injection, where the plasma 
half-life was stated to be 240 min. We 
have recently calculated the half-life of 
purified human FSH (Metrodin) during 
continuous steady-state infusions in hy- 
pogonadotropic men. The FSH half-life 
for this material was 3.2 h by in vitro 
bioassay for a one-component fit and 0.9 
h (fast) and 8.3 h (slow) for a two- 
component fit (unpublished data). The 
half-life of endogenous and exogenous 
infused FSH appears to be more rapid 
when estimated by in vitro bioassay than 
by immunoassays. 
?? Urinary B-FSH in Various Species 
In vitro FSH bioassays can be utilized in 
a variety of animal species. We have 
validated the assay for the measurement 
of B-FSH in sex-a of sheep (Padmanabhan 
et al. 1989b). With the GABA for unex- 
tracted small quantities of urine, urinary 
B-FSH levels have been measured in rats 
during puberty (Dahl et al. 1988b), low- 
land gorillas (Dahl and Hsueh 1987), 
giant panda (Montfort et al. 1989), and 
killer whales (Walker et al. 1988). In all 
of these animal species, urinary esti- 
mates integrated pulsatile serum pat- 
terns (if they existed) and reduced the 
stress of handling and venipuncture. 
Urinary B-FSH was measured in male 
and female rats from birth to 40 days of 
age. Detectable urinary B-FSH levels 
were present during the neonatal period 
and throughout puberty. The urinary 
B-FSH profiles were highly correlated 
with serum B-FSH (r = 0.93). Urinary 
concentrations, however, were 50 times 
higher than in serum. In the lowland 
gorilla, a midcycle B-FSH surge was 
detected. Two peaks of FSH were present 
during the follicular phase in the gorilla 
as well as the giant panda. The latter 
likewise had a urinary periovulatory 
FSH peak. A similar bimodal urinary 
B-FSH pattern was found in the killer 
whale. This method of measurement 
therefore provides useful information 
regarding reproductive hormones, their 
regulation, and their reproductive cy- 
clicity in endangered species and marine 
mammals. This information can be skill- 
fully utilized in the management and 
breeding programs of these animals. 
The reasons for the greater urinary 
than serum B-FSH concentrations (loo- 
fold during the menstrual cycle in women 
and SO-fold during maturation in the rat) 
are not known (Dahl et al. 1988b). Cus- 
tomarily, in human studies, to satisfy the 
principle of using the standard derived 
from the same source as the test ma- 
terial, pituitary FSH standards have been 
used for serum FSH determinations and 
urinary FSH for urinary FSH estimates. 
Also, the methods of extraction for the 
Steelman-Pohley in vivo bioassay and 
immunoassay are different. Neverthe- 
less, with all these reservations, we have 
found the urinary FSH B-I ratio to be 
1.16 f 0.11 in postmenopausal women 
(Beitins et al. 1980). We have not yet 
made similar comparisons using the in 
vitro bioassay for FSH. Much additional 
work regarding FSH clearance needs to 
be performed to determine whether the 
urine contains a large proportion of the 
desialylated rapidly cleared FSH isoforms 
that still retain in vitro bioactivity. Thus, 
during puberty, when the urinary B-FSH 
levels have been shown to increase, but 
the serum B-FSH concentrations remain 
stable, urinary B-FSH determinations 
may shed more light upon the types of 
FSH isoforms that circulate and are 
excreted than the arduous task of per- 
forming chromatofocusing studies in sera 
with low values of B-FSH. 
?? summary 
The availability of the in vitro FSH 
bioassay enabled, for the first time, the 
beginning of studies regarding the 
neuroendocrine regulation of FSH 
biosynthesis and secretion according to 
models widely utilized for LH (I-LH 
pulse characteristics and B-LH circula- 
tory patterns). The ability to determine 
B-FSH pulses in serum has revealed that 
LH and FSH are differentially regulated 
and released in animals and man. In 
addition, studies with GnRH agonists 
and antagonists reveal differential regu- 
lation of B and I-LH secretion. During 
pregnancy, likewise, high circulating lev- 
els of B-FSH-like activity with low im- 
munoreactivity are present. Chromatofo- 
cusing patterns of serum have confirmed 
that changes in the FSH B-I ratio are 
associated with shifts in the FSH isoform 
patterns. Estrogenic stimulation (midcy- 
cle, therapy) increases serum FSH B-I 
ratio in women, but not men, and is 
associated with an increase in the rela- 
tively less acidic FSH isoforms. Gonadal 
peptides such as inhibin in both sexes 
may modulate B-FSH secretion. There- 
fore, the overall regulation of gona- 
dotropin synthesis, release, circulation 
time, receptor binding, and signal transduc- 
tion is regulated at the pituitary gona- 
dotrope. Small GnRH signals (in fre- 
quent and/or low amplitude) appear to 
promote FSH synthesis and release ptefer- 
entially until the signal has achieved the 
magnitude required for LH secretion. 
Then, with further maturation, gonadal 
peptides modulate FSH secretion, result- 
ing in relatively stable mean FSH values 
while LH secretion is augmented. Sex 
steroids, on the other hand, modulate LH 
secretion to a greater extent than FSH. 
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?? Future Perspectives 
Exciting studies are under way by sev- 
eral investigators utilizing recombinant 
FSH from cotransfection of the com- 
mon a and FSH j3 genes into eukaryotic 
cell lines (Hsueh et al. 1989). The recombi- 
nant FSH is bioactive and has an almost 
identical p1 as the purified pituitary FSH 
standard (NIADDK-hFSH-I-3). By utiliz- 
ing this methodology, large quantities of 
purified bioactive FSH can be made to 
be used as standards in assays, as well as 
physiologic and future clinical studies. 
In addition, by making single amino- 
acid substitutions in crucial points within 
the FSH sequence, alterations in glycosyl- 
ation and tertiary structure can be in- 
duced. These mutants provide unparal- 
leled opportunities for structure-func- 
tion studies. Once the true importance 
and role of the various FSH isoforms is 
determined, it will be possible to design 
FSH isoforms for desired functions: 
sialylated, long-lived for growth and 
maintenance of reproductive organs; 
desialylated, short-lived for acute dy- 
namic events, such as ovulation: and 
antagonistic FSH isoforms for potential 
use in contraception. 
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Molecular Genetics of the 
Thyrotropin Receptor 
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Thyroid-stimulating hormone (TSH) receptor has been cloned by a 
strategy exploiting its belonging to the superfQmily of G-protein-coupled 
receptors. Comparison with the luteinizing hormone and follicle- 
stimulating hormone receptors shows that the glycoprotein hormone 
receptors constitute a subfamily of G-protein-coupled receptors with a 
large extracellular domain probably responsible for hormone binding. 
The recombinant human TSH receptor stably expressed in cell lines 
provides the tool to identify the targets of autoimmune reactions leading 
to Graves’ disease and idiopathic myxedema. (Trends Endocrinol Metab 
1991; 2:151-156) 
Thyrotropin (thyroid-stimulating hor- 
mone, TSH), which is the main regulator 
of the thyroid gland [reviewed by 
Dumont et al. (1989a)], is responsible for 
the rapid control of thyroid function 
(thyroid hormone secretion), maintains 
Gilbert Vassart is at the Institute of Interdisci- 
plinary Research, and at the Faculty of Medi- 
cine and Service of Medical Genetics, Free 
University, Brussels, Belgium. Marc Parmen- 
tier, Fr&l&ick Libert, and Jacques Dumont 
are at the Institute of Interdisciplinary Re- 
search, Brussels, Belgium. 
the differentiated state of the gland (for 
example, expression of the thyroglobulin 
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iodide transport), and is the major 
growth factor for thyrocytes (Dumont et 
al. 1989b). In humans and dogs, at least, 
all of these TSH effects can be mimicked 
by the forskolin-induced rise of intracel- 
lular cyclic (c) AMP. Although this does 
not exclude a role for other regulatory 
cascades (in particular, the phospholi- 
pase C-phosphoinositides<alcium sys- 
tem) or for other growth factors (such as 
epidermal growth factor, EGF), it is well 
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accepted that modulation by TSH of the 
adenylyl-cyclase-protein-kinase-A system 
represents the principal pathway of thy- 
roid regulation (Dumont et al. 1989a). 
The concept of a TSH receptor in the 
plasma membrane and the experimental 
evidence for its existence provided a 
rationale for the pathophysiology of 
Graves’ disease and for some forms of 
idiopathic myxedema. Autoantibodies di- 
rected against the TSH receptor can 
either activate it, causing goiter and 
hyperthyroidism, or interfere with TSH 
binding and action, leading to involution 
of the gland and hypothyroidism (Rees- 
Smith et al. 1988). 
Its pivotal role in the understanding of 
thyroid physiology and pathology, and in 
the development of diagnostic assays for 
stimulating or blocking autoantibodies, 
prompted numerous studies aiming at 
the characterization, isolation, and fi- 
nally cloning of the TSH receptor. 
Whereas a coherent picture of the recep- 
tor emerged rather early ii-om affinity- 
labeling studies, mainly from the group 
of Rees-Smith (1988), the cloning at- 
tempts have long encountered failures, 
false leads, and frustration. This long- 
lasting fallow period has now yielded to 
an abundance of information. Following 
our initial report (Parmentier et al. 
1989), several groups have now cloned 
the TSH receptor almost simultaneously 
(Nagayama et al. 1989; Misrahi et al. 
1990; Lindsay et al. 1990; Akamizu et al. 
1990), exploiting breakthroughs in the 
related fields of G-protein-coupled re- 
ceptors or LH-CC receptor cloning 
(Loosfelt et al. 1989; McFarland et al. 
1989). 
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